ライフサイエンスコーパス: creatinine clearance

1 er moderate to severe AKI (>50% reduction in creatinine clearance).

2 itial diuresis, but no significant change in creatinine clearance.

3 biopsy-proven acute rejection and estimated creatinine clearance.

4 creatinine, BUN, folate concentrations, and creatinine clearance.

5 in less pronounced albuminuria and increased creatinine clearance.

6 HS diet did not affect creatinine clearance.

7 ea plasma levels and less severe decrease in creatinine clearance.

8 (1350-1800 mg/12 hr) corrected according to creatinine clearance.

9 rmalized renal blood flow, but did not alter creatinine clearance.

10 uch as elevated blood pressure and decreased creatinine clearance.

11 d creatinine clearance, and endogenous 24-hr creatinine clearance.

12 35 mL/minute (95% CI = 3.98-16.77) in GFR or creatinine clearance.

13 d be needed to achieve a desired Css,avg and creatinine clearance.

14 type, BMI, average drug dose, adherence, and creatinine clearance.

15 aft nephropathy (CAN), serum creatinine, and creatinine clearance.

16 in aggregate was not associated with reduced creatinine clearance.

17 7% by Cockcroft-Gault equation, and 14.8% by creatinine clearance.

18 hod imprecision attenuated associations with creatinine clearance.

19 rum creatinine (SCr)-based GFR estimates, or creatinine clearance.

20 t of apolipoprotein A-I, HDL cholesterol, or creatinine clearance.

21 m of age, body weight, creatinine level, and creatinine clearance.

22 files, and 24-hour urine for proteinuria and creatinine clearance.

23 < 0.0001) levels, as well as improvement of creatinine clearance.

24 data from 214 adult critically-ill patients (creatinine clearance 0-236mL/min; 29 receiving renal rep

25 data from 214 adult critically-ill patients (creatinine clearance 0-236mL/min; 29 receiving renal rep

26 Mean estimated creatinine clearance 1 year posttransplant was 93.2+/-33

27 %), heart rate (-14%), blood pressure (-7%), creatinine clearance (-12%), energy cost of walking (-22

28 -12 mL/min/1.73 m; Cockcroft-Gault estimated creatinine clearance, 125+/-33 and 85+/-22 mL/min/1.73 m

29 tion (467+/-74 versus 174+/-23 mug/d), lower creatinine clearance (126+/-29 versus 452+/-63 mul/min),

30 85+/-22 mL/min/1.73 m, and endogenous 24-hr creatinine clearance, 133+/-38 and 86+/-24 mL/min/1.73 m

31 ced to 30 mg per day if one or more factors (creatinine clearance 15-50 mL/min, low bodyweight [</=60

32 model, elevated circulating ouabain reduced creatinine clearance (-18%, p < 0.05), increased urinary

33 serum creatinine 6 months and the estimated creatinine clearance 2 years after transplantation.

34 since LTX, and creatinine 1.8 to 4.0 mg/dL, creatinine clearance 20 to 60 mL/min, or both, were rand

35 were subjected to 5/6 subtotal nephrectomy (creatinine clearance, 25% normal).

36 mg/L and >/=4 mg/L extended to patients with creatinine clearance 30 to <50 mL/min.

37 ically suppressed HIV-infected adults with a creatinine clearance 30 to <50 mL/minute receiving TDF 3

38 misation or during the trial if patients had creatinine clearance 30-50 mL/min, bodyweight 60 kg or l

39 , 1.23-, 1.61-, and 1.47-fold enhancement of creatinine clearance, 3000-Da dextran clearance, 70 000-

40 Subjects with preexisting renal impairment (creatinine clearance, 40-60 mL/minute) received 75 mg os

41 years), weight 51 kg (range, 38-80 kg), and creatinine clearance 43.9 mL/minute (range, 30.9-49.7 mL

42 9.7 (12.2) years, weight 74.5 (20.3) kg, and creatinine clearance 56.8 (38.2) mL/minute were enrolled

43 +/- 0.7 mg/dL), or Cockroft Gault calculated creatinine clearance (58.6 +/- 19.7; 59.8 +/- 20.5 mL/mi

44 m creatinine (0.97-0.99 mg/dL), and baseline creatinine clearance (85.0-85.4 mL/minute).

45 years; 95% CI: 1.6 to 4.8); and had a lower creatinine clearance (-9.9 ml/min; 95% CI: -11.3 to -8.4

46 Data to estimate creatinine clearance according to the Cockcroft-Gault an

47 e from 10,236 patients, and data to estimate creatinine clearance according to the six- and four-vari

48 eservation by HMPox100% led to a doubling of creatinine clearance after 90 and 120 min of reperfusion

49 ria, increased serum creatinine, and reduced creatinine clearance (AKI), but there were no changes ov

50 ncology Group performance status, WBC count, creatinine clearance, albumin, AST, number of study drug

51 The renal allograft function by calculated creatinine clearance also significantly improved at 40.6

52 arkers (haematocrit, cTnI-hs, cystatin C, or creatinine clearance) also outperformed the HAS-BLED and

53 kidney injury, as reflected by the measured creatinine clearance, alters both pharmacokinetics and p

54 roup with no significant change in estimated creatinine clearance and a trend for plasma cystatin to

55 The diabetic 10% hypomorphs had comparable creatinine clearance and albumin excretion to wild-type

56 evated plasma creatinine and urea, decreased creatinine clearance and albuminuria) were progressively

57 sed a transient rise in plasma Pi levels and creatinine clearance and an increase in phosphaturia wit

58 72 hours, there was a decrease in estimated creatinine clearance and an increase in plasma cystatin

59 angiotensin II type 1 receptor reduced renal creatinine clearance and apical ENaC localization, and c

60 ant decreases in cross-sectional measures of creatinine clearance and GFR in the tenofovir group comp

61 Creatinine clearance and glomerular filtration rate (GFR

62 Patient creatinine clearance and graft status was followed up po

63 00 mg daily, which was adjusted according to creatinine clearance and hemoglobin values.

64 leeding, mild anemia, and a lower calculated creatinine clearance and less likely to be female or hav

65 parathyroidectomized rats also led to higher creatinine clearance and lower plasma calcium levels but

66 Doripenem clearance was correlated with creatinine clearance and peripheral volume of distributi

67 Ambrisentan improved creatinine clearance and podocyte effacement in eNOS-def

68 gatran before the procedure was based on the creatinine clearance and procedure-related bleeding risk

69 led to statistically significant declines in creatinine clearance and serious renal adverse events (d

70 ntravenous zoledronic acid 4 mg adjusted for creatinine clearance and subcutaneous placebo (n = 1,020

71 The decrease in creatinine clearance and the increase in the excretion o

72 c association between percentage decrease in creatinine clearance and the number of doses of tenofovi

73 Changes in potassium excretion, creatinine clearance, and body weight also were evaluate

74 imated GFR (eGFR), Cockcroft-Gault estimated creatinine clearance, and endogenous 24-hr creatinine cl

75 cure, bacteriological clearance, daily serum creatinine clearance, and estimated creatinine clearance

76 reased renal blood flow, oliguria, decreased creatinine clearance, and increased serum creatinine.

77 ance, changes in CD4 cell counts, calculated creatinine clearance, and lipid levels.

78 ST-segment elevation myocardial infarction, creatinine clearance, and troponin ratio were all indepe

79 indings (low baseline hemoglobin and reduced creatinine clearance), antiplatelet agent-related factor

80 Surprisingly, renal creatinine clearance as estimated from mass, age, and pl

81 The mean creatinine clearance at 1 and 3 years is 58 mL/min and 6

82 versely proportionally related to calculated creatinine clearance at doses of 10.1 and 12.0 mg/m2/d.

83 Despite similar serum creatinine levels, creatinine clearance averaged 20 points lower among trea

84 Patients with creatinine clearance below 30 were excluded.

85 not affect the time course of creatinine and creatinine clearance but did increase plasma urea, urea/

86 to high in the podocytes markedly decreased creatinine clearance, but minimally increased albumin ex

87 ths, and 8 patients matched by age, sex, and creatinine clearance, but with intact parathyroid hormon

88 of the serum creatinine level, reduction in creatinine clearance by 50% or more, progression to end-

89 talization: age, Charlson comorbidity score, creatinine clearance, calcium level, below-normal white

90 on and arithmetic mean +/- SE Cockroft-Gault creatinine clearance calculations, respectively, were 1.

91 >/=2, and >/=4 mg/L were determined for each creatinine clearance category (>/=80 mL/min, 50 to <80 m

92 evaluate the association between calculated creatinine clearance (CCC)-based contrast dose and renal

93 imated kidney function using Cockcroft-Gault creatinine clearance (CCl), Modification of Diet in Rena

94 Unique calculated variables included creatinine clearance (cCrCl) and Pediatric End-Stage Liv

95 Calculated creatinine clearance (Cockcroft and Gault formula) at 1

96 Estimated creatinine clearance (Cockcroft-Gault) from baseline out

97 Estimated renal creatinine clearance correlated with the extent of activ

98 iruses BKV and JCV and their relationship to creatinine clearance (CrCl) in a longitudinal study of 4

99 9 mg kg(-1)) did not change MAP, HR, RBF, or creatinine clearance (CrCl) in SD rats (n = 7).

100 versus warfarin across the range of baseline creatinine clearance (CrCl) in the ENGAGE AF-TIMI 48 tri

101 tients with volume overload and an estimated creatinine clearance (CrCl) of 20 to 80 ml/min were rand

102 Efficacy of formulas calculating creatinine clearance (CrCl) to determine renal function

103 Pretreatment renal function was defined as creatinine clearance (CrCl) using the Cockcroft-Gault eq

104 ese values were used to assign a category of creatinine clearance (CrCl) using the Cockcroft-Gault fo

105 If the calculated DD creatinine clearance (CrCl) was <65 mL/min, then the kid

106 At 7 days in 2K, serum creatinine clearance (CrCl) was decreased only in CsA/SR

107 were measured at study week 2, and rates of creatinine clearance (CrCl) were estimated using the Coc

108 =0.03) and a trend towards higher calculated creatinine clearance (CrCl), (58.4 ml/min vs. 54.3 ml/mi

109 statin C equation to that of 24-hour urinary creatinine clearance (CrCl), Cockcroft-Gault (CG), and p

110 Among patients with reduced creatinine clearance (CrCl), lack of adjustment of the m

111 The performance of creatinine clearance (CrCl), Modification of Diet in Ren

112 d on the creatinine level and the calculated creatinine clearance (CrCl).

113 onor hypertension, and had a lower estimated creatinine clearance (CrCl, all P < 0.01) compared with

114 ndomly assigned 134 adult patients with CKD (creatinine clearance [CrCl] 15 to 30 ml/min per 1.73 m(2

115 any renal impairment (creatinine >1.0 mg/dl, creatinine clearance [CrCl] or estimated glomerular filt

116 Creatinine clearance declined by an average of 0.34 ml/m

117 Creatinine clearance decreased similarly in both groups.

118 After reperfusion, 1) creatinine clearance decreased; 2) HO-1 mRNA and protein

119 r transient ischemic attack, diabetes, lower creatinine clearance, decreased hematocrit, aspirin ther

120 lic blood pressure were largely similar, and creatinine clearance did not differ between groups.

121 ration, renal sodium and chloride excretion, creatinine clearance, diuretic therapy, pH, known diabet

122 of renal function and routine monitoring of creatinine clearance during follow-up, tenofovir can be

123 The estimated creatinine clearance during sustained low-efficiency dia

124 with hemoglobin <11.5 g/dl and an estimated creatinine clearance (eCrCl) <50 ml/min per 1.73 m(2).

125 tio, spot urine albumin to creatinine ratio, creatinine clearance, estimated glomerular filtration ra

126 +/-0.29 mg/dL; corresponding mean calculated creatinine clearance estimates were 70+/-18, 73+/-17, an

127 Creatinine clearance fell from 109.8 +/- 22.3 mL/min per

128 reatinine, serum aspartate aminotransferase, creatinine clearance, fractional excretion of Na(+), and

129 Reductions in creatinine clearance from baseline were calculated and p

130 e use of statin, we found that the change in creatinine clearance from preoperative to postoperative

131 serum cystatin C and the reduced inulin and creatinine clearance from the circulation, suggested tha

132 can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in co

133 can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).

134 ent RD was defined as a relative decrease of creatinine clearance >/= 25% over baseline at 3 months.

135 on), 14 264 patients with nonvalvular AF and creatinine clearance >/=30 mL/min were randomized to riv

136 For patients with creatinine clearance >/=80 mL/min, only approximately 65

137 eved Css,avg >/=2mg/L; but for patients with creatinine clearance >/=80mL/min target attainment was <

138 eved Css,avg >/=2mg/L; but for patients with creatinine clearance >/=80mL/min target attainment was <

139 individuals with cardiovascular disease and creatinine clearance >30 ml/min) and examined post hoc t

140 inant polycystic kidney disease and baseline creatinine clearance>70 ml/min were followed annually fo

141 polycystic kidney disease (ADPKD; estimated creatinine clearance, >/=60 ml per minute), the vasopres

142 The PRECISE-DAPT score (age, creatinine clearance, haemoglobin, white-blood-cell coun

143 eep with nonhypotensive hyperdynamic sepsis, creatinine clearance halved (32 to 16 mL/min, ratio [95%

144 rebrovascular accident, smoking history, and creatinine clearance (hemoglobin level showed a strong t

145 ogen, sICAM-1, homocysteine, lipoprotein(a), creatinine clearance, high-density lipoprotein cholester

146 r body mass index (BMI), male sex, increased creatinine clearance, higher lipoprotein(a) level, prote

147 ared with the UW group (area under the curve creatinine clearance; HMP 9.8+/-7.3, HOC 2.2+/-1.7, UW 1

148 Six-hour creatinine clearance, hourly plasma/urinary furosemide c

149 ls, creatinine-based estimation equations or creatinine clearance; however, each of these methods has

150 ST deviation (HR, 1.39; 95% CI, 1.19-1.63), creatinine clearance (HR, 0.88; 95% CI, 0.83-0.94), Kill

151 infarction, femoral access for angiography, creatinine clearance, hypercholesterolemia, and arterial

152 eventually progressed to CKD, with decreased creatinine clearance, hyperphosphatemia, and renal fibro

153 1 month and 1 year posttransplant, estimated creatinine clearance improved from 59+/-13 mL/min at 1 m

154 rrelation between renal blood flow index and creatinine clearance in patients with septic acute kidne

155 atients were on continuous hemodialysis, and creatinine clearance in the other patients was 10-143 mL

156 predicted (p = 0.019) sustained elevation of creatinine clearance in these patients over the first we

157 Endogenous creatinine clearance is the most common method used to m

158 Creatinine clearance is usually increased by statins.

159 Creatinine clearance, kidney graft size, and glomerular

160 epatitis B virus surface antigen, pregnancy, creatinine clearance less than 60 mL per min, treatment

161 0 mg/day (P75) at 1-year postconversion were creatinine clearance less than 60 mL/min (odds ratio [OR

162 tive Oncology Group performance status of 2, creatinine clearance less than 60 mL/min, grade >/= 2 he

163 Karnofsky performance status of 60% to 70%, creatinine clearance less than 60 mL/min, visceral metas

164 In multivariate models, age and baseline creatinine clearance less than 90 mL/min predicted decli

165 level, folate, serum albumin and creatinine, creatinine clearance, lipid status, body mass index (BMI

166 The progressive kidney (creatinine levels, creatinine clearance), liver (transaminase activities, b

167 groups (age >/= 75 years, stage III myeloma, creatinine clearance < 60 mL/min).

168 h advanced chronic kidney disease (estimated creatinine clearance < or =30 mL/min) (n = 1305) or end-

169 ney for elimination, such that patients with creatinine clearance <25 ml/min were excluded from all t

170 c obstructive pulmonary disease, anemia, and creatinine clearance <30 ml/min were independent predict

171 tients with advanced chronic kidney disease (creatinine clearance <30 ml/min) and those on dialysis.

172 For creatinine clearance <30 mL/min, 100% of patients receiv

173 venting stroke specifically in patients with creatinine clearance <30 ml/min.

174 0-3.0) or rivaroxaban (20 mg daily; 15 mg if creatinine clearance <50 mL/min), double blind.

175 inine increase of >/=0.5 mg/dL [>44 umol/L], creatinine clearance <50 mL/min, or level of PO4 <2 mg/d

176 The inclusion of creatinine clearance <60 mL/min and prior stroke or tran

177 renal impairment (Cockcroft-Gault estimated creatinine clearance <60 ml/min or doubling of plasma cr

178 Among 2179 patients with CKD (creatinine clearance <60 mL/min), baseline troponin elev

179 s were independently predicted by older age, creatinine clearance <60 mL/min, treatment with coronary

180 Chronic kidney disease was defined as creatinine clearance <60 mL/min.

181 n a non-dialysis day), >80% of patients with creatinine clearance <80mL/min achieved Css,avg >/=2mg/L

182 n a non-dialysis day), >80% of patients with creatinine clearance <80mL/min achieved Css,avg >/=2mg/L

183 Creatinine clearance measured when study drug was stoppe

184 tment WRF (a decrease of >20% from screening creatinine clearance measurement at any time point durin

185 nto the study, contributing 1,660 individual creatinine clearance measures.

186 did so on more than or equal to 50% of their creatinine clearance measures.

187 fovir alafenamide had a smaller reduction in creatinine clearance (median change in estimated glomeru

188 Augmented renal clearance was defined by a creatinine clearance more than or equal to 130 mL/min/1.

189 djusted for traditional CVD risk factors and creatinine clearance, NGAL was a significant predictor o

190 igher TNFalpha was associated with decreased creatinine clearance, nonsmoking status, anemia, and gre

191 r institution; 1490 of 3986 had an estimated creatinine clearance of <60 mL/min and were enrolled.

192 ency preoperatively (defined as an estimated creatinine clearance of <60 mL/min determined by the Coc

193 dipstick analysis (7 [7%] of 1012 subjects); creatinine clearance of <90 mL/min (195 [18%] of 1071 su

194 ce daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body

195 icating worse health status) or an estimated creatinine clearance of 30 to 69 ml per minute to receiv

196 that enrolled patients with CKD (defined as creatinine clearance of 30-50 ml/min) and reported data

197 y (or 30 mg once per day for patients with a creatinine clearance of 30-50 mL/min, bodyweight <60 kg,

198 notable for a hemoglobin of 10.8 g/dL and a creatinine clearance of 36 mL/min.

199 aive HIV-infected patients with an estimated creatinine clearance of 50 mL per min or higher from 178

200 atinine of 140 micromol/L and mean estimated creatinine clearance of 57 ml/min at the end of follow-u

201 ey volume of 750 ml or more and an estimated creatinine clearance of 60 ml per minute or more, in a 2

202 raft function persists with a current median creatinine clearance of 60 mL/min.

203 The patients had a median age of 73 years, creatinine clearance of 62 ml per minute, and CIRS score

204 t-naive HIV-infected women with an estimated creatinine clearance of 70 mL/min or higher from 80 cent

205 sistance to emtricitabine and tenofovir, and creatinine clearance of 70 mL/min or higher.

206 NA concentrations of at least 5 log10 IU/mL, creatinine clearance of at least 1.0 mL/s, and a platele

207 5 times the upper limit of normal or less, a creatinine clearance of at least 30 mL/min, and a Karnof

208 ow reserve, adequate hepatic function, and a creatinine clearance of at least 50 mL per min.

209 mes the upper limit of normal, and estimated creatinine clearance of at least 50 mL/min (by the Cockc

210 r at least 6 months before enrolment and had creatinine clearance of at least 50 mL/min.

211 r at least 6 months before enrolment and had creatinine clearance of at least 50 mL/min.

212 In patients with a calculated serum creatinine clearance of more than 60 mg/min, no change i

213 prehensive metabolic panel with a calculated creatinine clearance of more than 60 mL per minute.

214 , normal blood cell counts, and a calculated creatinine clearance of more than 60 mL per minute.

215 c 300% hypermorphs had approximately 1/3 the creatinine clearance of wild-type mice, >20x their album

216 e GNC (n = 4) and all had estimated baseline creatinine clearances of <30ml/min.

217 0.5 vs SCS 2.7 +/- 0.7 mg/dL; P = 0.11) and creatinine clearance on day 10 (NEVKP, 65.9 +/- 18.8 mL/

218 The creatinine clearance on day 4 was increased in NEVKP-pre

219 emphasizes the effect of patient weight and creatinine clearance on pharmacokinetics.

220 ow-up sessions every 12 weeks, participants' creatinine clearance on PrEP was estimated and in a subs

221 1.1 to 2.6] or 2.1 [95% CI 1.4 to 3.3]), and creatinine clearance (OR 1.7; 95% CI 1.1 to 2.5).

222 ckcroft-Gault] 1.9 [95% CI 0.9 to 3.9]), and creatinine clearance (OR 2.0; 95% CI 1.0 to 4.2).

223 on, plasma B-type natriuretic peptide (BNP), creatinine clearance, or diastolic stage.

224 wever, no significant change of systemic BP, creatinine clearance, or markers of renal fibrosis, and

225 ion modeling suggested that age (P = 0.001), creatinine clearance (P = 0.01), and height z score (P =

226 Serum aldosterone correlated negatively with creatinine clearance (P<0.01) and positively with renal

227 d cystatin C (P<0.001), and higher estimated creatinine clearance (P=0.017).

228 BMI (P<0.001) and creatinine clearance (P=0.031) remained associated with

229 ower serum creatinine (P < 0.05), and higher creatinine clearances (P < 0.01) compared with rAAV1-GFP

230 , and the combination of MCP-1, AAG, TF, and creatinine clearance plus C4 was a good diagnostic test

231 NGAL together with creatinine clearance plus MCP-1 was an excellent diagnos

232 s680638 (P = 0.022) in HMCN1 with calculated creatinine clearance progression were also observed.

233 r ejection fraction (r = -0.134; p = 0.014), creatinine clearance (r = -0.224; p < 0.001), B-type nat

234 P < 0.001), heart rate (r = 0.60, P < 0.05), creatinine clearance (r = 0.79, P < 0.05), negative flui

235 clearance did not show any relationship with creatinine clearance (r(2) = 0.008), APACHE II score, or

236 A model that included creatinine clearance (R(2)CHADS(2)) improved net reclass

237 data from 162 adult critically ill patients (creatinine clearance range, 5.4-211 mL/min) were used to

238 , 1.009; 95% CI, 1.002-1.017; P = .01) and a creatinine clearance rate >/=53 mL/min (OR, 1.024; 95% C

239 Only baseline creatinine clearance rate >/=53 mL/min predicted 6-week

240 ared kidneys, we also quantified the average creatinine clearance rate per glomerulus.

241 te was 22.7 (5.2) mL/min and the mean plasma creatinine clearance rate was 20.7 (4.8) mL/min.

242 d prechemotherapy values, platelet count and creatinine clearance rate, predict IA outcome and strati

243 iphered creatinine excretion then yields the creatinine clearance rate.

244 ncentrations with reduced urinary calcium to creatinine clearance ratios (CCCR) in comparison with FH

245 heir albumin excretion more than 10-fold but creatinine clearance remained high.

246 Patients whose creatinine clearance returned to baseline (or nearly) we

247 Creatinine clearance should be calculated for every elde

248 Clinic and ambulatory BP, creatinine clearance, sodium and protein intake, and gly

249 ding demographics, clinical characteristics, creatinine clearance, ST deviation, index diagnosis, and

250 fter transplant was associated with improved creatinine clearance, suggesting continued adaptation ov

251 such as BP and systolic function; by 10 yr, creatinine clearance surpassed these other risk factors,

252 Twenty-four hours after a 90% reduction in creatinine clearance, the rise in SCr was 246% with norm

253 ose, glycosylated hemoglobin, creatinine, or creatinine clearance; therefore, PAI-1R may prevent prog

254 s patient group, with sustained elevation of creatinine clearance throughout the first week in ICU.

255 ood pressure, sympathetic nerve activity and creatinine clearance to diabetic Cav2.2(+/+) mice.

256 At 1 yr, the contribution of creatinine clearance to mortality risk rivaled tradition

257 imal serum creatinine levels and recovery of creatinine clearance to normal values compared with CS.

258 Estimated GFR and 24-hr plasma creatinine clearance underestimate GFR with greater vari

259 enal function criteria should enable liberal creatinine clearance, unless the investigational agent i

260 ratio of the volume of contrast media to the creatinine clearance (V/CrCl) has been shown to correlat

261 nt-related concern, then patients with lower creatinine clearance values of > 30 mL/min should be inc

262 was defined as excessive if not reduced when creatinine clearance was < 50 mL/min for eptifibatide or

263 The slope of calculated creatinine clearance was -0.66 mL/min/month over 6 month

264 ng a median of 72 weeks, the mean decline in creatinine clearance was -2.9% (95% CI -2.4 to -3.4; ptr

265 Median change in estimated creatinine clearance was 1.2 mL/min in the tacrolimus gr

266 Serum creatinine and creatinine clearance was 1.9+/-0.8 and 59+/-11 in contro

267 Baseline creatinine clearance was 52.4+/-17.8 mL/min vs. 53.4+/-2

268 Cardiovascular Project, mean Cockcroft-Gault creatinine clearance was 55 +/- 24 ml/min and estimated

269 Calculated creatinine clearance was 66+/-26 mL/min at 2 years.

270 Reduced creatinine clearance was a strong, independent predictor

271 Creatinine clearance was also similar between groups (in

272 The annual mean calculated creatinine clearance was also stable over time.

273 Greater rate of decline in creatinine clearance was associated with greater age, co

274 The creatinine clearance was calculated for estimation of th

275 with incident microalbuminuria and change in creatinine clearance was examined among 1279 participant

276 t EOP, liver function tests were similar but creatinine clearance was higher in micafungin- vs standa

277 The creatinine clearance was inversely associated with preop

278 ation of waist circumference with decline in creatinine clearance was observed.

279 Creatinine clearance was preserved in the Dox + Erl rats

280 nse to furosemide also became important when creatinine clearance was reduced to less than 40 mL/min/

281 -2.2, HTK 5.6+/-1.9 mm Hg/min; P=0.006), and creatinine clearance was significantly higher compared w

282 Mean calculated creatinine clearance was significantly lower in group B

283 Renal function assessed by creatinine clearance was similar for both groups.

284 Measured creatinine clearance was strongly associated with the am

285 Adjusted creatinine clearance was unchanged over the 10 days.

286 Proteinuria, but not creatinine clearance, was associated with higher percent

287 enal function, as measured by an increase in creatinine clearance, was maintained and the rate of inc

288 The mean rates of decline in creatinine clearance were 10.9 and 15.6 ml per minute pe

289 Among BOC recipients, lower baseline Hb and creatinine clearance were associated with incident anemi

290 abetes mellitus (NODM), serum creatinine and creatinine clearance were evaluated.

291 of high grade proteinuria, urine sodium and creatinine clearance were measured.

292 Iothalamate clearance, SCr, and creatinine clearance were obtained at each visit.

293 ly serum creatinine clearance, and estimated creatinine clearance were recorded.

294 The mean Cockroft-Gault estimated creatinine clearances were 47.1+/-24.2, 37.2+/-16.3, and

295 1.1, 1.9+/-0.9, and 2.2+/-1.3 mg/dl and mean creatinine clearances were 66+/-15, 68+/-14, and 58+/-10

296 Eight-hour urinary creatinine clearances were collected daily, as the prima

297 fection, but in patients with BKV infection, creatinine clearances were lower at times when viral she

298 potassium, lithium, para-aminohippurate, and creatinine clearances were measured before, during, and

299 the GFR and the Cockcroft-Gault estimate of creatinine clearance, were examined against GFR measured

300 ot change renal blood flow, urine output, or creatinine clearance, whereas infusion of Nomega-nitro-L